Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases

The objective of the study was to compare the treatment outcomes in patients with occult primary carcinoma with axillary lymph node metastasis who were treated with mastectomy or with intent to preserve the breast. From 1951 to 1998, 479 female patients were registered with axillary lymph node metas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of surgical oncology 2001-06, Vol.8 (5), p.425-431
Hauptverfasser: Vlastos, G, Jean, M E, Mirza, A N, Mirza, N Q, Kuerer, H M, Ames, F C, Hunt, K K, Ross, M I, Buchholz, T A, Buzdar, A U, Singletary, S E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 431
container_issue 5
container_start_page 425
container_title Annals of surgical oncology
container_volume 8
creator Vlastos, G
Jean, M E
Mirza, A N
Mirza, N Q
Kuerer, H M
Ames, F C
Hunt, K K
Ross, M I
Buchholz, T A
Buzdar, A U
Singletary, S E
description The objective of the study was to compare the treatment outcomes in patients with occult primary carcinoma with axillary lymph node metastasis who were treated with mastectomy or with intent to preserve the breast. From 1951 to 1998, 479 female patients were registered with axillary lymph node metastasis from an unknown primary. After clinical workup, including mammography, 45 patients retained this diagnosis and received treatment for T0 N1-2 M0 carcinoma of the breast. Clinical and pathological data were collected retrospectively, and survival was calculated from the date of initial diagnosis using the Kaplan-Meier method. Median follow-up time was 7 years. Median age was 54 years (range, 32-79). Clinical nodal status was N1 in 71% and N2 in 29% of the patients. Surgical treatment was mastectomy in 29% and an intent to preserve the breast in 71% of the patients. Locoregional radiotherapy was used in 71% and systemic chemoendocrine therapy was used in 73% of the patients. Of the 13 mastectomy patients, only one had a primary tumor discovered in the specimen. Two patients (4%) were ultimately diagnosed with lung cancer and neuroendocrine tumor. No significant difference was detected between mastectomy and breast preservation in locoregional recurrence (15% versus 13%), distant metastases (31% versus 22%), or 5-year survival (75% vs. 79%). Regardless of surgical therapy, the most important determinant of survival was the number of positive nodes. Five-year overall survival was 87% with 1-3 positive nodes compared with 42% with > or =4 positive nodes (P < .0001). Occult primary carcinoma with axillary metastases can be treated with preservation of the breast without a negative impact on local control or survival.
doi_str_mv 10.1007/s10434-001-0425-6
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70936185</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70936185</sourcerecordid><originalsourceid>FETCH-LOGICAL-c324t-70c64ad3f6eb7caaa9de6a061d47861b2a7eed7a74767ef09a5715169ec45c683</originalsourceid><addsrcrecordid>eNpdkUtLxDAUhYMozjj6A9xIcOGumrR5tEsRR4UBN7oOaXrrZOhjTFJ1_r0pLQiu8vrO4eYchC4puaWEyDtPCctYQghNCEt5Io7QkvJ4w0ROj-OeiDwpUsEX6Mz7XeRkRvgpWlDKiORULpFfg_a2tI0NB9zXuHTxHPDegQf3pYPtO2w7HLaAQ3wKLXRh5HpjhmbkbKvdARvtjO36Vk_KLtjuA3_bsMX6xzbNiLQQorP24M_RSa0bDxfzukLv68e3h-dk8_r08nC_SUyWspBIYgTTVVYLKKXRWhcVCE0ErZjMBS1TLQEqqSWTQkJNCs0l5VQUYBg3Is9W6Gby3bv-cwAfVGu9gThOB_3glSRFJmjOI3j9D9z1g-vibCpNZcbSGG6E6AQZ13vvoFbz5xUlaqxDTXWoGLMa61Aiaq5m46FsofpTzPlnv8Beh_I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>227342425</pqid></control><display><type>article</type><title>Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Vlastos, G ; Jean, M E ; Mirza, A N ; Mirza, N Q ; Kuerer, H M ; Ames, F C ; Hunt, K K ; Ross, M I ; Buchholz, T A ; Buzdar, A U ; Singletary, S E</creator><creatorcontrib>Vlastos, G ; Jean, M E ; Mirza, A N ; Mirza, N Q ; Kuerer, H M ; Ames, F C ; Hunt, K K ; Ross, M I ; Buchholz, T A ; Buzdar, A U ; Singletary, S E</creatorcontrib><description>The objective of the study was to compare the treatment outcomes in patients with occult primary carcinoma with axillary lymph node metastasis who were treated with mastectomy or with intent to preserve the breast. From 1951 to 1998, 479 female patients were registered with axillary lymph node metastasis from an unknown primary. After clinical workup, including mammography, 45 patients retained this diagnosis and received treatment for T0 N1-2 M0 carcinoma of the breast. Clinical and pathological data were collected retrospectively, and survival was calculated from the date of initial diagnosis using the Kaplan-Meier method. Median follow-up time was 7 years. Median age was 54 years (range, 32-79). Clinical nodal status was N1 in 71% and N2 in 29% of the patients. Surgical treatment was mastectomy in 29% and an intent to preserve the breast in 71% of the patients. Locoregional radiotherapy was used in 71% and systemic chemoendocrine therapy was used in 73% of the patients. Of the 13 mastectomy patients, only one had a primary tumor discovered in the specimen. Two patients (4%) were ultimately diagnosed with lung cancer and neuroendocrine tumor. No significant difference was detected between mastectomy and breast preservation in locoregional recurrence (15% versus 13%), distant metastases (31% versus 22%), or 5-year survival (75% vs. 79%). Regardless of surgical therapy, the most important determinant of survival was the number of positive nodes. Five-year overall survival was 87% with 1-3 positive nodes compared with 42% with &gt; or =4 positive nodes (P &lt; .0001). Occult primary carcinoma with axillary metastases can be treated with preservation of the breast without a negative impact on local control or survival.</description><identifier>ISSN: 1068-9265</identifier><identifier>EISSN: 1534-4681</identifier><identifier>DOI: 10.1007/s10434-001-0425-6</identifier><identifier>PMID: 11407517</identifier><language>eng</language><publisher>United States: Springer Nature B.V</publisher><subject>Adult ; Aged ; Axilla - pathology ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - surgery ; Carcinoma - mortality ; Carcinoma - pathology ; Carcinoma - surgery ; Feasibility Studies ; Female ; Follow-Up Studies ; Humans ; Lymphatic Metastasis - pathology ; Mastectomy ; Middle Aged ; Neoplasm Recurrence, Local - pathology ; Neoplasms, Unknown Primary - mortality ; Neoplasms, Unknown Primary - pathology ; Neoplasms, Unknown Primary - surgery ; Survival Rate ; Treatment Outcome</subject><ispartof>Annals of surgical oncology, 2001-06, Vol.8 (5), p.425-431</ispartof><rights>The Society of Surgical Oncology, Inc. 2001</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c324t-70c64ad3f6eb7caaa9de6a061d47861b2a7eed7a74767ef09a5715169ec45c683</citedby><cites>FETCH-LOGICAL-c324t-70c64ad3f6eb7caaa9de6a061d47861b2a7eed7a74767ef09a5715169ec45c683</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11407517$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vlastos, G</creatorcontrib><creatorcontrib>Jean, M E</creatorcontrib><creatorcontrib>Mirza, A N</creatorcontrib><creatorcontrib>Mirza, N Q</creatorcontrib><creatorcontrib>Kuerer, H M</creatorcontrib><creatorcontrib>Ames, F C</creatorcontrib><creatorcontrib>Hunt, K K</creatorcontrib><creatorcontrib>Ross, M I</creatorcontrib><creatorcontrib>Buchholz, T A</creatorcontrib><creatorcontrib>Buzdar, A U</creatorcontrib><creatorcontrib>Singletary, S E</creatorcontrib><title>Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases</title><title>Annals of surgical oncology</title><addtitle>Ann Surg Oncol</addtitle><description>The objective of the study was to compare the treatment outcomes in patients with occult primary carcinoma with axillary lymph node metastasis who were treated with mastectomy or with intent to preserve the breast. From 1951 to 1998, 479 female patients were registered with axillary lymph node metastasis from an unknown primary. After clinical workup, including mammography, 45 patients retained this diagnosis and received treatment for T0 N1-2 M0 carcinoma of the breast. Clinical and pathological data were collected retrospectively, and survival was calculated from the date of initial diagnosis using the Kaplan-Meier method. Median follow-up time was 7 years. Median age was 54 years (range, 32-79). Clinical nodal status was N1 in 71% and N2 in 29% of the patients. Surgical treatment was mastectomy in 29% and an intent to preserve the breast in 71% of the patients. Locoregional radiotherapy was used in 71% and systemic chemoendocrine therapy was used in 73% of the patients. Of the 13 mastectomy patients, only one had a primary tumor discovered in the specimen. Two patients (4%) were ultimately diagnosed with lung cancer and neuroendocrine tumor. No significant difference was detected between mastectomy and breast preservation in locoregional recurrence (15% versus 13%), distant metastases (31% versus 22%), or 5-year survival (75% vs. 79%). Regardless of surgical therapy, the most important determinant of survival was the number of positive nodes. Five-year overall survival was 87% with 1-3 positive nodes compared with 42% with &gt; or =4 positive nodes (P &lt; .0001). Occult primary carcinoma with axillary metastases can be treated with preservation of the breast without a negative impact on local control or survival.</description><subject>Adult</subject><subject>Aged</subject><subject>Axilla - pathology</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - surgery</subject><subject>Carcinoma - mortality</subject><subject>Carcinoma - pathology</subject><subject>Carcinoma - surgery</subject><subject>Feasibility Studies</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Lymphatic Metastasis - pathology</subject><subject>Mastectomy</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasms, Unknown Primary - mortality</subject><subject>Neoplasms, Unknown Primary - pathology</subject><subject>Neoplasms, Unknown Primary - surgery</subject><subject>Survival Rate</subject><subject>Treatment Outcome</subject><issn>1068-9265</issn><issn>1534-4681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkUtLxDAUhYMozjj6A9xIcOGumrR5tEsRR4UBN7oOaXrrZOhjTFJ1_r0pLQiu8vrO4eYchC4puaWEyDtPCctYQghNCEt5Io7QkvJ4w0ROj-OeiDwpUsEX6Mz7XeRkRvgpWlDKiORULpFfg_a2tI0NB9zXuHTxHPDegQf3pYPtO2w7HLaAQ3wKLXRh5HpjhmbkbKvdARvtjO36Vk_KLtjuA3_bsMX6xzbNiLQQorP24M_RSa0bDxfzukLv68e3h-dk8_r08nC_SUyWspBIYgTTVVYLKKXRWhcVCE0ErZjMBS1TLQEqqSWTQkJNCs0l5VQUYBg3Is9W6Gby3bv-cwAfVGu9gThOB_3glSRFJmjOI3j9D9z1g-vibCpNZcbSGG6E6AQZ13vvoFbz5xUlaqxDTXWoGLMa61Aiaq5m46FsofpTzPlnv8Beh_I</recordid><startdate>20010601</startdate><enddate>20010601</enddate><creator>Vlastos, G</creator><creator>Jean, M E</creator><creator>Mirza, A N</creator><creator>Mirza, N Q</creator><creator>Kuerer, H M</creator><creator>Ames, F C</creator><creator>Hunt, K K</creator><creator>Ross, M I</creator><creator>Buchholz, T A</creator><creator>Buzdar, A U</creator><creator>Singletary, S E</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20010601</creationdate><title>Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases</title><author>Vlastos, G ; Jean, M E ; Mirza, A N ; Mirza, N Q ; Kuerer, H M ; Ames, F C ; Hunt, K K ; Ross, M I ; Buchholz, T A ; Buzdar, A U ; Singletary, S E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c324t-70c64ad3f6eb7caaa9de6a061d47861b2a7eed7a74767ef09a5715169ec45c683</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Axilla - pathology</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - surgery</topic><topic>Carcinoma - mortality</topic><topic>Carcinoma - pathology</topic><topic>Carcinoma - surgery</topic><topic>Feasibility Studies</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Lymphatic Metastasis - pathology</topic><topic>Mastectomy</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasms, Unknown Primary - mortality</topic><topic>Neoplasms, Unknown Primary - pathology</topic><topic>Neoplasms, Unknown Primary - surgery</topic><topic>Survival Rate</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vlastos, G</creatorcontrib><creatorcontrib>Jean, M E</creatorcontrib><creatorcontrib>Mirza, A N</creatorcontrib><creatorcontrib>Mirza, N Q</creatorcontrib><creatorcontrib>Kuerer, H M</creatorcontrib><creatorcontrib>Ames, F C</creatorcontrib><creatorcontrib>Hunt, K K</creatorcontrib><creatorcontrib>Ross, M I</creatorcontrib><creatorcontrib>Buchholz, T A</creatorcontrib><creatorcontrib>Buzdar, A U</creatorcontrib><creatorcontrib>Singletary, S E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Annals of surgical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vlastos, G</au><au>Jean, M E</au><au>Mirza, A N</au><au>Mirza, N Q</au><au>Kuerer, H M</au><au>Ames, F C</au><au>Hunt, K K</au><au>Ross, M I</au><au>Buchholz, T A</au><au>Buzdar, A U</au><au>Singletary, S E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases</atitle><jtitle>Annals of surgical oncology</jtitle><addtitle>Ann Surg Oncol</addtitle><date>2001-06-01</date><risdate>2001</risdate><volume>8</volume><issue>5</issue><spage>425</spage><epage>431</epage><pages>425-431</pages><issn>1068-9265</issn><eissn>1534-4681</eissn><abstract>The objective of the study was to compare the treatment outcomes in patients with occult primary carcinoma with axillary lymph node metastasis who were treated with mastectomy or with intent to preserve the breast. From 1951 to 1998, 479 female patients were registered with axillary lymph node metastasis from an unknown primary. After clinical workup, including mammography, 45 patients retained this diagnosis and received treatment for T0 N1-2 M0 carcinoma of the breast. Clinical and pathological data were collected retrospectively, and survival was calculated from the date of initial diagnosis using the Kaplan-Meier method. Median follow-up time was 7 years. Median age was 54 years (range, 32-79). Clinical nodal status was N1 in 71% and N2 in 29% of the patients. Surgical treatment was mastectomy in 29% and an intent to preserve the breast in 71% of the patients. Locoregional radiotherapy was used in 71% and systemic chemoendocrine therapy was used in 73% of the patients. Of the 13 mastectomy patients, only one had a primary tumor discovered in the specimen. Two patients (4%) were ultimately diagnosed with lung cancer and neuroendocrine tumor. No significant difference was detected between mastectomy and breast preservation in locoregional recurrence (15% versus 13%), distant metastases (31% versus 22%), or 5-year survival (75% vs. 79%). Regardless of surgical therapy, the most important determinant of survival was the number of positive nodes. Five-year overall survival was 87% with 1-3 positive nodes compared with 42% with &gt; or =4 positive nodes (P &lt; .0001). Occult primary carcinoma with axillary metastases can be treated with preservation of the breast without a negative impact on local control or survival.</abstract><cop>United States</cop><pub>Springer Nature B.V</pub><pmid>11407517</pmid><doi>10.1007/s10434-001-0425-6</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1068-9265
ispartof Annals of surgical oncology, 2001-06, Vol.8 (5), p.425-431
issn 1068-9265
1534-4681
language eng
recordid cdi_proquest_miscellaneous_70936185
source MEDLINE; SpringerNature Journals
subjects Adult
Aged
Axilla - pathology
Breast Neoplasms - mortality
Breast Neoplasms - pathology
Breast Neoplasms - surgery
Carcinoma - mortality
Carcinoma - pathology
Carcinoma - surgery
Feasibility Studies
Female
Follow-Up Studies
Humans
Lymphatic Metastasis - pathology
Mastectomy
Middle Aged
Neoplasm Recurrence, Local - pathology
Neoplasms, Unknown Primary - mortality
Neoplasms, Unknown Primary - pathology
Neoplasms, Unknown Primary - surgery
Survival Rate
Treatment Outcome
title Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T18%3A57%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Feasibility%20of%20breast%20preservation%20in%20the%20treatment%20of%20occult%20primary%20carcinoma%20presenting%20with%20axillary%20metastases&rft.jtitle=Annals%20of%20surgical%20oncology&rft.au=Vlastos,%20G&rft.date=2001-06-01&rft.volume=8&rft.issue=5&rft.spage=425&rft.epage=431&rft.pages=425-431&rft.issn=1068-9265&rft.eissn=1534-4681&rft_id=info:doi/10.1007/s10434-001-0425-6&rft_dat=%3Cproquest_cross%3E70936185%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=227342425&rft_id=info:pmid/11407517&rfr_iscdi=true